Sakar Healthcare Limited has informed the Exchange about ACCORD Healthcare, UK secures EU variation approval for Imatinib (100 mg & 400 mg) with Sakar now positioned to supply their European market.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ACCORD Healthcare, UK (Sakar's partner) has secured EU variation approval for Imatinib tablets in 100 mg and 400 mg strengths. Imatinib is a critical oncology drug used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. With this approval in place, Sakar Healthcare is now positioned to manufacture and supply Imatinib for the European market through its partnership with ACCORD. The company operates in the active pharmaceutical ingredients and finished dosage formulations space. This expands Sakar's regulatory footprint in regulated European markets, though the announcement does not disclose expected order volumes, revenue contribution, or timelines.
Positive for the stock in the medium term as it opens access to a high-value regulated oncology market in Europe, but near-term impact depends on actual order flow and commercial volumes that have not been disclosed yet.